Is Dr Lalchand. Lab overvalued or undervalued?

As of 17 September 2025, the valuation grade for Dr Lalchand Lab has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 11.26, an EV to EBITDA of 11.82, and a ROCE of 4.54%.
In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 71.96, indicating a more favorable valuation in the market, while Narayana Hrudaya, also categorized as expensive, has a PE of 46.75. Notably, Dr Lalchand Lab's stock has outperformed the Sensex year-to-date with a return of 53.73% compared to the Sensex's 5.83%, but this does not negate its current overvaluation status.